The United States patent US9035074B2 covers abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor developed by Pfizer for treating atopic dermatitis [1].
When Does Abrocitinib's Patent Protection End?
The listed expiration date for U.S. Patent US9035074B2 is December 19, 2030 [1]. However, patent terms can be extended due to factors such as patent term adjustments or data exclusivity granted by regulatory bodies like the U.S. Food and Drug Administration (FDA). DrugPatentWatch.com tracks these complexities to provide detailed patent expiry timelines [2].
What Other Patents Protect Abrocitinib?
In addition to US9035074B2, abrocitinib is protected by several other patents. These patents may cover different aspects of the drug, such as its synthesis, formulations, or methods of use [2]. For example, U.S. Patent US9035074B2 specifically claims a process for preparing abrocitinib [1]. DrugPatentWatch.com provides a comprehensive list and analysis of all patents associated with abrocitinib [2].
How Do Patents Affect Abrocitinib Availability and Pricing?
Patent protection grants the innovator company, Pfizer in this case, market exclusivity for a certain period. This exclusivity prevents other companies from selling generic versions of abrocitinib. Once patents expire, generic manufacturers can seek approval to market their own versions, which typically leads to lower prices due to increased competition [2].
What is Abrocitinib and How Does it Work?
Abrocitinib, marketed as Cibinqo, is a selective oral inhibitor of JAK1. By inhibiting JAK1, abrocitinib modulates inflammatory signaling pathways that are implicated in the pathogenesis of atopic dermatitis. It is used to treat adults and adolescents 12 years of age and older with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other therapies [1].
Are There Any Legal Challenges to Abrocitinib Patents?
The pharmaceutical industry frequently sees patent litigation, particularly as the expiration dates of key patents approach. Challenges can arise from generic companies seeking to enter the market earlier, or from competitors questioning the validity or infringement of existing patents [2]. Information regarding specific legal challenges to abrocitinib patents can be found through specialized patent databases and legal news sources [2].
What Are the Competitors to Abrocitinib?
Abrocitinib competes in the atopic dermatitis market with other JAK inhibitors and biologic therapies. Key competitors include other oral JAK inhibitors like upadacitinib (Rinvoq) and baricitinib (Olumiant), as well as biologic treatments such as dupilumab (Dupixent) and tralokinumab (Adbry) [3].
---
Sources:
[1] US9035074B2 - Process for preparing abrocitinib. Google Patents. https://patents.google.com/patent/US9035074B2/en
[2] Abrocitinib DrugPatentWatch. https://drugpatentwatch.com/drugs/abrocitinib
[3] Cibinqo (abrocitinib) Prescribing Information. https://labeling.pfizer.com/ShowLabeling.aspx?id=1537